Related Experiment Videos
Gene therapy: recombinant adeno-associated virus vectors
J R Smith-Arica1, J S Bartlett
1Children's Research Institute, W531, 700 Children's Drive, Columbus, OH, 43205-2696, USA. SmithJ@pediatrics.ohio-state.edu
Current Cardiology Reports
|January 5, 2001
Summary
Recombinant adeno-associated virus (rAAV) vectors are advancing human gene therapy with improved production, targeting, and broader applications. These developments enhance gene delivery efficiency and expand therapeutic possibilities for various diseases.
Area of Science:
- Gene Therapy
- Virology
- Molecular Biology
Background:
- Recombinant adeno-associated virus (rAAV) vectors are crucial for human gene therapy due to their broad host range, low immunogenicity, and sustained gene expression.
- Numerous clinical trials are underway utilizing rAAV vectors for diverse disease paradigms.
Purpose of the Study:
- To provide an overview of current advancements in adeno-associated virus (AAV)-mediated gene delivery.
- To highlight key developments enhancing the utility and scope of rAAV vectors in gene therapy.
Main Methods:
- Review of recent literature on AAV vector technology.
- Analysis of new production and purification techniques.
- Examination of novel AAV serotypes and genome engineering strategies.
Main Results:
- Development of high-titer AAV preparations and improved purification methods.
- Introduction of alternative AAV serotypes and trans-splicing rAAV genomes.
- Identification of capsid regions for targeted vector modification.
Conclusions:
- Recent advancements have significantly improved rAAV vector performance, including host range, coding capacity, and results interpretation.
- Enhanced vector targeting capabilities are emerging, enabling precise gene delivery to specific cell populations.
- The versatility of rAAV vectors broadens the potential for therapeutic intervention in a wider array of diseases.